Jazan Development Company logo

Jazan Development Company (6090)

Market Closed
11 Jun, 12:00
XSAU XSAU
8. 06
+0.03
+0.3736%
- Market Cap
- P/E Ratio
60% Div Yield
61,432 Volume
- Eps
8.03
Previous Close
Add Transaction
Day Range
8.02 8.12
Year Range
7.55 11.5
Want to track 6090 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6090 closed yesterday higher at ﷼8.06, an increase of 0.3736% from Wednesday's close, completing a monthly decrease of -7.4627% or -﷼0.65. Over the past 12 months, 6090 stock gained 0.3736%.
6090 pays dividends to its shareholders, with the most recent payment made on Aug 22, 2017.
The last earnings report, released on May 15, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Jazan Development Company has completed 1 stock splits, with the recent split occurring on Dec 28, 2005.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on JPX (JPY).

6090 Chart

Jazan Development Company (6090) FAQ

What is the stock price today?

The current price is ﷼8.06.

On which exchange is it traded?

Jazan Development Company is listed on XSAU.

What is its stock symbol?

The ticker symbol is 6090.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 60%.

What is its market cap?

As of today, no market cap data is available.

Has Jazan Development Company ever had a stock split?

Jazan Development Company had 1 splits and the recent split was on Dec 28, 2005.

Jazan Development Company Profile

Professional Services Industry
Industrials Sector
Mr. Katsuhito Hashizume CEO
XSAU Exchange
SA0007879642 ISIN
Japan Country
58 Employees
29 Jun 2026 Last Dividend
- Last Split
- IPO Date

Overview

Human Metabolome Technologies, Inc. stands out as a biotechnology company with a keen focus on developing cutting-edge metabolomics technologies and solutions. Established in 2003 and operating out of Tsuruoka, Japan, this innovative company has carved a niche for itself in the realms of drug discovery, diagnosis, and food production. With a commitment to advancing scientific research and application, Human Metabolome Technologies fosters collaboration with prestigious institutions like the Institute for Advanced Biosciences and Keio University. This partnership aims to further the development of metabolome analysis technology, showcasing the company's dedication to pushing the boundaries of scientific exploration and application in metabolomics.

Products and Services

Human Metabolome Technologies, Inc. offers a comprehensive suite of metabolomics analysis services and solutions tailored to meet a wide range of scientific and industrial needs. Each service is designed with precision to provide valuable insights across various applications, ensuring clients achieve their research and development goals effectively.

  • Metabolome Analysis Services: At the core of its offerings, the company provides in-depth metabolome analysis to uncover the complete set of metabolites present in biological samples. This foundational service enables researchers to gain a comprehensive understanding of the metabolic profiles relevant to diseases, treatment effects, and nutritional statuses.
  • Global Profiling: This service offers an exhaustive analysis of metabolites, presenting a broad overview of the metabolic state of a sample. Global profiling is crucial for identifying novel biomarkers and understanding complex metabolic changes.
  • Targeted Assays: For more focused research requirements, targeted assays provide quantification of specific metabolites. This precise approach is pivotal in validating biomarkers and investigating targeted metabolic pathways.
  • Flux Analysis: Understanding metabolic fluxes is essential for unraveling the dynamics of metabolism. Flux analysis services offered by the company enable researchers to track the flow of metabolites through metabolic pathways, offering insights into cellular function and metabolic disorders.
  • Lipidomics: Focusing on the comprehensive study of cellular lipids, lipidomics services facilitate the exploration of lipid metabolism. This is particularly valuable for research in areas such as obesity, diabetes, and cardiovascular diseases.
  • Development of Biomarkers: One notable achievement in this area is the identification of Phosphorylethanolamine as a biomarker for major depressive disorder, measurable in blood plasma. The development of such biomarkers is integral for advancing diagnostics and personalized medicine.

In addition to these services, Human Metabolome Technologies tailors its approach to support various applications, including cancer metabolism, metabolic flux analysis, infectious diseases, basic science research, preclinical and clinical studies, food and nutrition, and microbiome research. Through this broad yet specialized service offering, the company addresses the diverse needs of its clientele, ultimately contributing to scientific advancement and innovation in biotechnology.

Contact Information

Address: 246-2 Mizukami Kakuganji
Phone: 81 3 3551 2180